Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
CAS PubMed Central Article PubMed Google Scholar
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
CAS Article PubMed Google Scholar
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
CAS PubMed Central Article PubMed Google Scholar
Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).
CAS PubMed Central Article PubMed Google Scholar
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
CAS Article PubMed Google Scholar
Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).
CAS PubMed Central Article PubMed Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
CAS Article PubMed Google Scholar
Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726–1737 (2019).
CAS PubMed Central Article PubMed Google Scholar
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503–509 (2022). This landmark article reports the sustained remissions and in vivo persistence of CD19-CAR T cells for more than 10 years after infusion, and hence highlights the long-term durability of clinical responses achieved using genetically engineered T cells.
CAS PubMed Central Article PubMed Google Scholar
Malmberg, K.-J. et al. Natural killer cell-mediated immunosurveillance of human cancer. Semin. Immunol. 31, 20–29 (2017).
CAS Article PubMed Google Scholar
Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502 (2008).
CAS PubMed Central Article PubMed Google Scholar
Joncker, N. T., Fernandez, N. C., Treiner, E., Vivier, E. & Raulet, D. H. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J. Immunol. 182, 4572–4580 (2009). This study elucidates the nature of NK cell responsiveness, which relies on the integration of both inhibitory and activating signalling cues to ensure self-tolerance and immunosurveillance over abnormal cells.
CAS Article PubMed Google Scholar
Joncker, N. T., Shifrin, N., Delebecque, F. & Raulet, D. H. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J. Exp. Med. 207, 2065–2072 (2010).
CAS PubMed Central Article PubMed Google Scholar
Burshtyn, D. N. et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4, 77–85 (1996).
CAS PubMed Central Article PubMed Google Scholar
Yokoyama, W. M. & Kim, S. How do natural killer cells find self to achieve tolerance? Immunity 24, 249–257 (2006).
CAS Article PubMed Google Scholar
Brodin, P., Lakshmikanth, T., Johansson, S., Kärre, K. & Höglund, P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 113, 2434–2441 (2009).
CAS Article PubMed Google Scholar
Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795–1799 (2000).
CAS Article PubMed Google Scholar
Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571–580 (2008).
CAS PubMed Central Article PubMed Google Scholar
López-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Control of metastasis by NK cells. Cancer Cell 32, 135–154 (2017).
Article CAS PubMed Google Scholar
Abel, A. M., Yang, C., Thakar, M. S. & Malarkannan, S. Natural killer cells: development, maturation, and clinical utilization. Front. Immunol. 9, 1869 (2018).
PubMed Central Article CAS PubMed Google Scholar
Dalle, J.-H. et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr. Res. 57, 649–655 (2005).
CAS Article PubMed Google Scholar
Strauss-Albee, D. M. et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci. Transl. Med. 7, 297ra115–297ra115 (2015).
PubMed Central Article CAS PubMed Google Scholar
Prager, I. & Watzl, C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J. Leukoc. Biol. 105, 1319–1329 (2019).
CAS Article PubMed Google Scholar
Wang, W., Erbe, A. K., Hank, J. A., Morris, Z. S. & Sondel, P. M. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front. Immunol. 6, 368 (2015).
PubMed Central PubMed Google Scholar
O’Leary, J. G., Goodarzi, M., Drayton, D. L. & von Andrian, U. H. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7, 507–516 (2006). This seminal study demonstrates that NK cells can mediate durable recall responses upon antigen re-exposure, establishing the concept of NK cell adaptive memory.
Article CAS PubMed Google Scholar
Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer cells. Nature 457, 557–561 (2009). This important article reveals self-renewing ‘memory’ NK cell subsets that can undergo secondary expansion and elicit strong adaptive immune responses upon viral challenge when transferred to naive animals.
CAS PubMed Central Article PubMed Google Scholar
Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. Proc. Natl Acad. Sci. USA 106, 1915–1919 (2009). This work pioneers the concept of cytokine-induced memory-like NK cells which elicit robust recall responses when transferred to naïve hosts.
CAS PubMed Central Article PubMed Google Scholar
Romee, R. et al. Cytokine activation induces human memory-like NK cells. Blood 120, 4751–4760 (2012).
CAS PubMed Central Article PubMed Google Scholar
Romee, R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med. 8, 357ra123 (2016).
PubMed Central Article CAS PubMed Google Scholar
Shapiro, R. M. et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J. Clin. Investig. https://doi.org/10.1172/JCI154334 (2022).
Article PubMed Central PubMed Google Scholar
Platonova, S. et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71, 5412–5422 (2011).
CAS Article PubMed Google Scholar
Sun, C. et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology 6, e1264562 (2017).
Article CAS PubMed Google Scholar
Spanholtz, J. et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS ONE 5, e9221 (2010).
PubMed Central Article CAS PubMed Google Scholar
Dolstra, H. et al. Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin. Cancer Res. 23, 4107–4118 (2017).
CAS Article PubMed Google Scholar
Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520–531 (2018). This article reports the first successful clinical application of CAR-modified NK immunotherapy in patients with CD19-positive haematologic malignancies.
CAS Article PubMed Google Scholar
Berrien-Elliott, M. M. et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discov. 10, 1854–1871 (2020).
CAS PubMed Central Article PubMed Google Scholar
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
留言 (0)